All Stories

  1. Relapse risk prediction in patients with first-episode bipolar disorder: development, external validation, and pharmacotherapy associations of a machine learning model
  2. Psychopathic Traits Associate With Later Schizophrenia
  3. Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment
  4. Long term safety of ADHD medication in patients with schizophrenia spectrum disorders
  5. Metabolic Alterations in Human Post‐Mortem Frontal Cortex and Cerebrospinal Fluid Associated With High Levels of Nicotine Metabolite Cotinine
  6. Continuous Dopamine D2 Receptor Blockade and Long-Term Outcome in First-Episode Schizophrenia
  7. Is it Possible To Identify Patients After Their First Hospitalization for a Psychotic Disorder Who Do Not Use Anti-Psychotics and are Not Later Rehospitalized?
  8. miRNA profiling of hiPSC-derived neurons from monozygotic twins discordant for schizophrenia
  9. Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia
  10. Metabolic alterations in human post-mortem frontal cortex and cerebrospinal fluid associated with high levels of nicotine metabolite cotinine
  11. The challenges of antipsychotic polypharmacy
  12. Antipsychotic Monotherapy vs Polytherapy for Pneumonia Risk—Reply
  13. Labor market marginalization in individuals with bipolar disorder: a Swedish nationwide register-based sibling comparison study
  14. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder
  15. Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: A subanalysis of a systematic review and meta-analysis with meta-regression of moderators
  16. Dosing levels of antipsychotics and mood stabilizers in bipolar disorder: A Nationwide cohort study on relapse risk and treatment safety
  17. Severe side effects of the most effective schizophrenia medication
  18. Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia
  19. Association of obesity to reaction time and visual memory in schizophrenia
  20. Characteristics of high-dose benzodiazepine use: nationwide cohort study on new benzodiazepine users with 5-year follow-up
  21. Aberrant type 2 dopamine receptor availability in violent offenders with psychopathy
  22. Astrocytes Regulate Neuronal Network Burst Frequency Through NMDA Receptors in a Species- and Donor-Specific Manner
  23. Cardiovascular mortality in bipolar disorder: Population‐based cohort study
  24. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case–control study in Finland
  25. Real‐world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within‐subject analyses of two nationwide cohorts
  26. Medication use and sickness absence from work in bipolar disorder: a nationwide register‐based study
  27. Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case–Control Database Study
  28. Integrative metabolomics-genomics analysis identifies key networks in a stem cell-based model of schizophrenia
  29. Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study
  30. Development and Validation of a Machine Learning–Based Model of Mortality Risk in First-Episode Psychosis
  31. Navigated and individual α-peak-frequency–guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
  32. Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis
  33. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data
  34. Relative Risk of Breast Cancer Associated With Prolactin-Increasing Antipsychotic Use
  35. Long-term benzodiazepine use and risk of labor market marginalization in Finland: A cohort study with 5-year follow-up
  36. Effect of severity of depression on augmentation of antidepressant medication in young adults with depression
  37. Non-adherence to mood stabilizers and antipsychotics among persons with bipolar disorder – A nationwide cohort study
  38. β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control Study
  39. Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
  40. Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia
  41. Association of pharmacological treatments and real‐world outcomes in borderline personality disorder
  42. Cohort profile: SUPER-Finland – the Finnish study for hereditary mechanisms of psychotic disorders
  43. Functional Characterization of Six SLCO1B1 (OATP1B1) Variants Observed in Finnish Individuals with a Psychotic Disorder
  44. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study
  45. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
  46. Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients
  47. Psychotic depression and deaths due to suicide
  48. Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis
  49. Validation of the collaborative outcomes study on health and functioning during infection times (COH-FIT) questionnaire for adults
  50. Factors and their weight in reducing life expectancy in schizophrenia
  51. Antipsychotic Use and Risk of Low-Energy Fractures in People With Schizophrenia: A Nationwide Nested Case-Control Study in Finland
  52. Mortality in psychotic depression: 18-year follow-up study
  53. Twenty‐year medication use trends in first‐episode bipolar disorder
  54. Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse
  55. Mu-opioid receptor system modulates responses to vocal bonding and distress signals in humans
  56. Real‐world effectiveness of mood stabilizer use in schizophrenia
  57. Allopurinol, dipyridamole and calcium channel blockers in the treatment of bipolar disorder – A nationwide cohort study
  58. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts
  59. Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder
  60. Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study
  61. Clozapine and the risk of haematological malignancies – Authors' reply
  62. Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study
  63. Real-world effectiveness studies of low doses of antipsychotics – Authors' reply
  64. Differences in psychosocial functioning between psychotic disorders in the Finnish SUPER study
  65. Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
  66. Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors
  67. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland
  68. Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends
  69. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders
  70. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study
  71. Aberrant motor contagion of emotions in psychopathy and high-functioning autism
  72. Female Psychopathy and Mortality
  73. Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
  74. Clinical and societal burden of incident major depressive disorder: A population‐wide cohort study in Stockholm
  75. Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
  76. Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder
  77. Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
  78. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic
  79. Brain structural alterations in autism and criminal psychopathy
  80. The iPSC perspective on schizophrenia
  81. Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia
  82. Switches and early discontinuations of antidepressant medication in young adults with depression
  83. Exploring the relation between high-activity COMT Val158Met genotype and psychopathy in male offenders
  84. Correspondence regarding De Girolamo et al., 2021 ‘A multinational case–control study comparing forensic and non-forensic patients with schizophrenia spectrum disorders: the EU-VIORMED project’
  85. Reaction Time and Visual Memory in Connection to Hazardous Drinking Polygenic Scores in Schizophrenia, Schizoaffective Disorder and Bipolar Disorder
  86. Clozapine, Long-Acting Injectables (and Polypharmacy?) Superior in U.S. and International Registries
  87. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland
  88. Reaction Time and Visual Memory in Connection to Alcohol Use in Persons with Bipolar Disorder
  89. Associations of age, sex, sexual abuse, and genotype with monoamine oxidase a gene methylation
  90. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study
  91. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
  92. Antipsychotic discontinuation: mind the patient and the real-world evidence
  93. Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
  94. Continuity of antipsychotic medication use among migrant and Finnish-born populations with a psychotic disorder: a register-based study
  95. Molecular signaling pathways underlying schizophrenia
  96. Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder
  97. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort
  98. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry
  99. Brain Basis of Psychopathy in Criminal Offenders and General Population
  100. Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
  101. Registry-based studies: What they can tell us, and what they cannot
  102. Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases
  103. Changes in the metabolic profile of human male postmortem frontal cortex and cerebrospinal fluid samples associated with heavy alcohol use
  104. Morbidity and mortality in schizophrenia with comorbid substance use disorders
  105. Voluntary patient safety incidents reporting in forensic psychiatry—What do the reports tell us?
  106. Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
  107. Effectiveness of pharmacotherapies for delusional disorder in a Swedish national cohort of 9076 patients
  108. Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia
  109. Risk of labour market marginalisation among young refugees and non-refugee migrants with common mental disorders
  110. Real‐world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation‐wide cohort of 125 556 patients
  111. Long-Term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
  112. Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences
  113. Rejoinder to rejoinder to commentary
  114. Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: A Finnish nationwide cohort study
  115. Employment among people with schizophrenia or bipolar disorder: A population‐based study using nationwide registers
  116. Medication management of antipsychotic treatment in schizophrenia—A narrative review
  117. Causes of death in a nationwide cohort of community-dwellers with Alzheimer’s disease
  118. P.810Real-world effectiveness of mood stabilizer use in persons with schizophrenia
  119. Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland
  120. Commentary on Robert Whitaker's viewpoint
  121. Detection of medications associated with Alzheimer's disease using ensemble methods and cooperative game theory
  122. Corrigendum to “Monoamine oxidase A genotype and methylation moderate the association of maltreatment and aggressive behaviour” [Behav. Brain Res. 382 (2020) 112476]
  123. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis
  124. Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia
  125. Length of Hospital Stay for Hip Fracture and 30-Day Mortality in People With Alzheimer’s Disease: A Cohort Study in Finland
  126. Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia
  127. Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real‐World Study Across Antipsychotics
  128. Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease
  129. Risk and risk factors for disability pension among patients with treatment resistant depression– a matched cohort study
  130. The clinical course of schizophrenia in women and men—a nation-wide cohort study
  131. T208. EFFECTIVENESS OF PHARMACOLOGICAL THERAPIES FOR DELUSIONAL DISORDER
  132. Monoamine oxidase A genotype and methylation moderate the association of maltreatment and aggressive behaviour
  133. A Systematic Literature Review of Neuroimaging of Psychopathic Traits
  134. Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer’s Disease
  135. Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease
  136. Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring
  137. Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia
  138. 20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)
  139. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
  140. The Risk of Head Injuries Associated With Antipsychotic Use Among Persons With Alzheimer's disease
  141. Opioid Use After Hospital Care due to Hip Fracture Among Community-Dwelling Persons With and Without Alzheimer’s Disease
  142. Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease
  143. Metformin and Risk of Alzheimer’s Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study
  144. Correction: Neurobiological roots of psychopathy
  145. Substance Abuse and Excessive Mortality Among Forensic Psychiatric Patients: A Finnish Nationwide Cohort Study
  146. Sex-specific transcriptional and proteomic signatures in schizophrenia
  147. Neurobiological roots of psychopathy
  148. Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer’s disease
  149. Cortical structure abnormalities in females with conduct disorder prior to age 15
  150. Adherence to psychotropic medication in completed suicide in Sweden 2006–2013: a forensic-toxicological matched case-control study
  151. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study
  152. Hospital-Treated Pneumonia Associated with Opioid Use Among Community Dwellers with Alzheimer’s Disease
  153. Antiepileptic Drugs and Accumulation of Hospital Days Among Persons With Alzheimer's Disease
  154. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
  155. Increased [³H]quisqualic acid binding density in the dorsal striatum and anterior insula of alcoholics: A post-mortem whole-hemisphere autoradiography study
  156. Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer’s disease—nested case-control study
  157. Changes in patient safety culture: A patient safety intervention for Finnish forensic psychiatric hospital staff
  158. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review
  159. Trajectories of sickness absence, disability pension and unemployment in young immigrants with common mental disorders
  160. Antiepileptic Drug Use Is Associated with an Increased Risk of Pneumonia Among Community-Dwelling Persons with Alzheimer’s Disease-Matched Cohort Study
  161. Incidence of head injury and traumatic brain injury among people with Alzheimer’s disease
  162. Manifesto for an international digital mental health network
  163. Risk of Treatment Failure: Response to Ghosh and Noble
  164. Associations of Psychopathic Traits With Local and Global Brain Network Topology in Young Adult Women
  165. Response to the editorial on antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
  166. Concomitant use of benzodiazepines and opioids in community‐dwelling older people with or without Alzheimer's disease—A nationwide register‐based study in Finland
  167. Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer’s disease
  168. Comorbid opioid use is undertreated among forensic patients with schizophrenia
  169. Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease
  170. Incidence and prevalence of antiepileptic drugs use in persons with Alzheimer's disease.
  171. Systemic Estrogen Use and Discontinuation After Alzheimer’s Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study
  172. Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study
  173. Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease
  174. Antiepileptic Drug Use and the Risk of Stroke Among Community‐Dwelling People With Alzheimer Disease: A Matched Cohort Study
  175. Burden for Parents of Patients With Schizophrenia—A Nationwide Comparative Study of Parents of Offspring With Rheumatoid Arthritis, Multiple Sclerosis, Epilepsy, and Healthy Controls
  176. Risk of Treatment Failure: Response to Czobor and Volavka
  177. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia
  178. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
  179. Hospitalization after Oral Antibiotic Initiation in Finnish Community Dwellers with and without Alzheimer’s Disease: Retrospective Register-Based Cohort Study
  180. Mortality in schizophrenia: 30‐year nationwide follow‐up study
  181. The risk of Alzheimer's disease associated with benzodiazepines and related drugs: a nested case–control study
  182. Editorial: let's take a break from studying the PPI‐fracture association—Authors’ reply
  183. Trends in the long‐term use of benzodiazepine anxiolytics and hypnotics: A national register study for 2006 to 2014
  184. Cause-specific mortality in Finnish forensic psychiatric patients
  185. Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder
  186. Associations of monoamine oxidase A gene first exon methylation with sexual abuse and current depression in women
  187. Comparison of dispensed medications and forensic‐toxicological findings to assess pharmacotherapy in the Swedish population 2006 to 2013
  188. Use of Antiepileptic Drugs and Dementia Risk—an Analysis of Finnish Health Register and German Health Insurance Data
  189. Impact of opioid initiation on antipsychotic and benzodiazepine and related drug use among persons with Alzheimer's disease
  190. Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study
  191. Initiation and long‐term use of benzodiazepines and Z‐drugs in bipolar disorder
  192. Platelet monoamine oxidase activity and interpersonal violence in male suicide attempters
  193. Associations Between MAOA‐uVNTR Genotype, Maltreatment, MAOA Methylation, and Alcohol Consumption in Young Adult Males
  194. Amygdala-orbitofrontal structural and functional connectivity in females with anxiety disorders, with and without a history of conduct disorder
  195. Firesetting and general criminal recidivism among a consecutive sample of Finnish pretrial male firesetters: A register-based follow-up study
  196. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
  197. Genome-Wide Association Studies of a Broad Spectrum of Antisocial Behavior
  198. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer’s Disease
  199. Risk of disability pension in first and second generation immigrants: the role of age and region of birth in a prospective population-based study from Sweden
  200. Healthcare use among immigrants and natives in Sweden on disability pension, before and after changes of regulations
  201. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study
  202. Nurses’ Views Highlight a Need for the Systematic Development of Patient Safety Culture in Forensic Psychiatry Nursing
  203. De‐escalation techniques used, and reasons for seclusion and restraint, in a forensic psychiatric hospital
  204. Drug exposure in register-based research—An expert-opinion based evaluation of methods
  205. Trajectories and characteristics of work disability before and after acute myocardial infarction
  206. Use of lithium in patients with unipolar depression – Author's reply
  207. Is Alzheimer’s Disease Associated with Previous Opioid Use?
  208. Effects of Scheduled Waiting for Psychotherapy in Patients With Major Depression
  209. Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations
  210. Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer’s disease: a nationwide matched cohort study
  211. The Association of Ambient Temperature and Violent Crime
  212. White matter correlates of psychopathic traits in a female community sample
  213. Brain structure abnormalities in young women who presented conduct disorder in childhood/adolescence
  214. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study
  215. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia
  216. Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer’s disease
  217. Hospital-treated mental and behavioral disorders and risk of Alzheimer's disease: A nationwide nested case-control study
  218. Psychopathy and Mortality
  219. Screening approach for identifying candidate drugs and drug‐drug interactions related to hip fracture risk in persons with Alzheimer disease
  220. Incident Use of a Potentially Inappropriate Medication and Hip Fracture in Community-Dwelling Older Persons With Alzheimer’s Disease
  221. Seasonal variation of hospital violence, seclusion and restraint in a forensic psychiatric hospital
  222. Use of benzodiazepines and related drugs is associated with a risk of stroke among persons with Alzheimer’s disease
  223. Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease
  224. Risk of Alzheimer’s disease among users of postmenopausal hormone therapy: A nationwide case-control study
  225. Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer’s Disease
  226. Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer’s disease in 2005-2011
  227. Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer’s Disease
  228. Anticholinergic Exposure and Risk of Pneumonia in Persons with Alzheimer’s Disease: A Nested Case-Control Study
  229. Antidepressant use and risk of hip fractures among community‐dwelling persons with and without Alzheimer's disease
  230. Risk of Hip Fracture in Benzodiazepine Users With and Without Alzheimer Disease
  231. Antipsychotic Use and Risk of Hospitalization or Death Due to Pneumonia in Persons With and Those Without Alzheimer Disease
  232. Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease – exposure-matched cohort study
  233. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer’s disease
  234. A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer’s Disease in the US and Finland
  235. Differences in analgesic use in community‐dwelling persons with and without Alzheimer's disease
  236. Risk Factors for Initiation of Potentially Inappropriate Medications in Community-Dwelling Older Adults with and without Alzheimer’s Disease
  237. Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study
  238. Real‐world effectiveness of antipsychotics
  239. Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics
  240. Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons
  241. The effects of a HTR2B stop codon and testosterone on energy metabolism and beta cell function among antisocial Finnish males
  242. Fire-setting performed in adolescence or early adulthood predicts schizophrenia: a register-based follow-up study of pre-trial offenders
  243. Drug use in persons with and without Alzheimer's disease aged 90 years or more
  244. Genome-wide association study of antisocial personality disorder
  245. Influence of a HTR2B Stop Codon on Glucagon Homeostasis and Glucose Excursion in Non-Diabetic Men
  246. Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study
  247. Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study
  248. Increased steroid hormone dehydroepiandrosterone and pregnenolone levels in post-mortem brain samples of alcoholics
  249. Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer’s Disease
  250. Nurses' Time Use in Forensic Psychiatry
  251. Month and Season of Birth as a Risk Factor for Alzheimer’s Disease: A Nationwide Nested Case-control Study
  252. Incidence of antidepressant use in community‐dwelling persons with and without Alzheimer's disease: 13‐year follow‐up
  253. Conduct disorder in females is associated with reduced corpus callosum structural integrity independent of comorbid disorders and exposure to maltreatment
  254. Impulsive alcohol-related risk-behavior and emotional dysregulation among individuals with a serotonin 2B receptor stop codon
  255. Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer’s disease in a Finnish nationwide cohort
  256. Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons
  257. Long-term use of benzodiazepines: Definitions, prevalence and usage patterns – a systematic review of register-based studies
  258. The Incidence of Benzodiazepine and Related Drug Use in Persons with and without Alzheimer’s Disease
  259. Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer’s Disease
  260. Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study
  261. Baseline symptom severity predicts serotonin transporter change during psychotherapy in patients with major depression
  262. Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study
  263. Hospital-treated suicide attempts among Finnish fire setters: a follow-up study
  264. Opioid abuse and hospitalization rates in patients with schizophrenia
  265. A Pilot Study of Group Administered Metacognitive Training (MCT) for Schizophrenia Patients in a High-Security Forensic Setting: Subjective Training Success and Health-Related Quality of Life
  266. Decreased [³H]naloxone Binding in the Dentate Gyrus of Cloninger Type 1 Anxiety-Prone Alcoholics: A Postmortem Whole-Hemisphere Autoradiography Study
  267. Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer’s disease
  268. Factors Associated with Hospitalization for Blood-Borne Viral Infections Among Treatment-Seeking Illicit Drug Users
  269. Hospitalization in a Cohort Seeking Treatment for Illicit Drug Use in Finland
  270. Psychotropic drugs and homicide: A prospective cohort study from Finland
  271. Potential Years of Life Lost Due to Premature Mortality Among Treatment-Seeking Illicit Drug Users in Finland
  272. From prescription drug purchases to drug use periods – a second generation method (PRE2DUP)
  273. Psychopathic traits among a consecutive sample of Finnish pretrial fire-setting offenders
  274. [3H]Ifenprodil binding in post-mortem brains of Cloninger type 1 and 2 alcoholics: A whole-hemisphere autoradiography study
  275. Characteristics of drug-abusing females with and without children seeking treatment in Helsinki, Finland
  276. Basal insulin secretion, PCL-R and recidivism among impulsive violent alcoholic offenders
  277. Mortality of firesetters: A follow-up study of Finnish male firesetters who underwent a pretrial forensic examination in 1973–1998
  278. Predictors for initiation of pharmacological prophylaxis in patients with newly diagnosed bipolar disorder—A nationwide cohort study
  279. Concomitant Use of Acetylcholine Esterase Inhibitors and Urinary Antispasmodics Among Finnish Community-Dwelling Persons With Alzheimer Disease
  280. Increased Metabotropic Glutamate 2/3 Receptor Binding in the Perigenual Anterior Cingulate Cortex of Cloninger Type 2 Alcoholics: A Whole-Hemisphere Autoradiography Study
  281. Antipsychotic Treatment and Mortality in Schizophrenia
  282. High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort
  283. Patterns and 14-year trends in mortality among illicit drug users in Finland: The HUUTI study
  284. Genetic background of extreme violent behavior
  285. Lower [3H]Citalopram Binding in Brain Areas Related to Social Cognition in Alcoholics
  286. Corrigendum to “Mortality among clients seeking treatment for buprenorphine abuse in Finland” [Drug Alcohol Depend. 133 (2013) 391–397]
  287. Antipsychotic Doses Among Community-Dwelling Persons With Alzheimer Disease in Finland
  288. Antipsychotic Polypharmacy among a Nationwide Sample of Community-Dwelling Persons with Alzheimer's Disease
  289. The C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation
  290. Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland
  291. Association of Socio-Demographic Factors, Sick-Leave and Health Care Patterns with the Risk of Being Granted a Disability Pension among Psychiatric Outpatients with Depression
  292. Mortality among forensic psychiatric patients in Finland
  293. Factors associated with buprenorphine compared to amphetamine abuse among clients seeking treatment in Finland
  294. Metacognitive group training for forensic and dangerous non‐forensic patients with schizophrenia: A randomised controlled feasibility trial
  295. AMPA receptors in post-mortem brains of Cloninger type 1 and 2 alcoholics: A whole-hemisphere autoradiography study
  296. Mortality among clients seeking treatment for buprenorphine abuse in Finland
  297. Patient Safety Culture in Two Finnish State-Run Forensic Psychiatric Hospitals
  298. Previous forensic mental examination is a useful marker indicating effective violence relapse prevention among psychotic patients
  299. Cluster-Randomized Controlled Trial of Reducing Seclusion and Restraint in Secured Care of Men With Schizophrenia
  300. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research – the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study
  301. Endogenous cannabinoids in amygdala and hippocampus in post-mortem brains of Cloninger type 1 and 2 alcoholics
  302. Cavum septum pellucidum and psychopathy
  303. Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis
  304. mGluR1/5 receptor densities in the brains of alcoholic subjects: A whole-hemisphere autoradiography study
  305. Violent behaviour in a forensic psychiatric hospital in Finland: an analysis of violence incident reports
  306. Coexisting social conditions and health problems among clients seeking treatment for illicit drug use in Finland: The HUUTI study
  307. Clozapine resistance—Augmentation strategies
  308. Atypical nucleus accumbens morphology in psychopathy: Another limbic piece in the puzzle
  309. Decreased GABAA benzodiazepine binding site densities in postmortem brains of Cloninger type 1 and 2 alcoholics
  310. Extended‐release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial
  311. Word List Learning in Patients with Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy
  312. Influence of Serotonin Transporter Gene Polymorphism (5-HTTLPR Polymorphism) on the Relation between Brain 5-HT Transporter Binding and Heart Rate Corrected Cardiac Repolarization Interval
  313. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia – A path model investigation
  314. Using the HCR-20 to Predict Aggressive Behavior among Men with Schizophrenia Living in the Community: Accuracy of Prediction, General and Forensic Settings, and Dynamic Risk Factors
  315. Twelve-year trend in treatment seeking for buprenorphine abuse in Finland
  316. Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial
  317. Ketamine in treatment-resistant major depression
  318. Methylphenidate in the treatment of amphetamine dependence: a double-blind randomised, placebo-controlled trial
  319. Naltrexone depot implant in the treatment of co-morbid amphetamine and opioid dependence
  320. Sociodemographic Characteristics and Drug Abuse Patterns of Treatment-Seeking Illicit Drug Abusers in Finland, 1997–2008: The Huuti Study
  321. Description of long-term polypharmacy among schizophrenia outpatients
  322. Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort
  323. Rorschach assessment of personality functioning in patients with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy
  324. Exome Sequencing Followed by Large-Scale Genotyping Suggests a Limited Role for Moderately Rare Risk Factors of Strong Effect in Schizophrenia
  325. Whole-hemisphere autoradiography of 5-HT1B receptor densities in postmortem alcoholic brains
  326. Polypharmacy With Antipsychotics, Antidepressants, or Benzodiazepines and Mortality in Schizophrenia
  327. Naltrexone Implant for the Treatment of Polydrug Dependence: A Randomized Controlled Trial
  328. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia
  329. Reply to Drs. Nauta and van Domburg
  330. Examining the effectiveness of antipsychotic medication in first-episode psychosis
  331. Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment
  332. The Substance Use among Forensic Psychiatric Patients
  333. The net effect of smoking on healthcare and welfare costs. A cohort study
  334. Toward Molecular Psychotherapy of Depression?
  335. The Patient–Therapist Interaction and the Recognition of Affects during the Process of Psychodynamic Psychotherapy for Depression
  336. Statin usage and all‐cause and disease‐specific mortality in a nationwide study
  337. Erratum: Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia
  338. The place of observational studies in assessing the effectiveness of depot antipsychotics
  339. Cortex and amygdala morphology in psychopathy
  340. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia
  341. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia
  342. Add‐on mirtazapine improves depressive symptoms in schizophrenia: a double‐blind randomized placebo‐controlled study with an open‐label extension phase
  343. Interrelationship between core interventions and core competencies of forensic psychiatric nursing in Finland
  344. Psychopathy, PCL-R, and MAOA genotype as predictors of violent reconvictions
  345. Psychopathic brain -- an unknown challenge for treatment
  346. Gender differences in brain serotonin transporter availability in panic disorder
  347. Group psychoeducation for long‐term offender patients with schizophrenia: An exploratory randomised controlled trial
  348. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial
  349. Serotonin‐transporter‐linked promoter region polymorphism and serotonin transporter binding in drug‐naïve patients with major depression
  350. Extrapyramidal side-effects and dopamine D2/3receptor binding in substantia nigra
  351. MAOA Alters the Effects of Heavy Drinking and Childhood Physical Abuse on Risk for Severe Impulsive Acts of Violence Among Alcoholic Violent Offenders
  352. Endogenous cannabinoids in post-mortem brains of Cloninger type 1 and 2 alcoholics
  353. EFFECTS OF ADD-ON MIRTAZAPINE ON NEUROCOGNITION IN SCHIZOPHRENIA: AN OPEN LABEL EXTENSION PHASE OF A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, AND BOTH PHASES
  354. The Intergenerational Cycle of Criminality—Association with Psychopathy*
  355. Seasonal variation of seclusion incidents from violent and suicidal acts in forensic psychiatric patients
  356. Dopamine transporter binding in females with panic disorder may vary with clinical status
  357. Predicting forensic admission among the mentally ill in a multinational setting: A Bayesian modelling approach
  358. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study
  359. Mortality in patients with schizophrenia – Author's reply
  360. Incidence of cancer and antidepressant medication: Record linkage study
  361. Incidence of cancer and statin usage—Record linkage study
  362. Cardiac repolarization and striatal dopamine transporter function are interrelated
  363. Abnormal hippocampal shape in offenders with psychopathy
  364. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
  365. Dopamine D2/3receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine
  366. Abnormal Cortical Morphology in Offenders with Psychopathy
  367. Low non-oxidative glucose metabolism and violent offending: An 8-year prospective follow-up study
  368. Recidivistic offending and mortality in alcoholic violent offenders: A prospective follow-up study
  369. Altered hemispheric balance of temporal cortex dopamine D2/3 receptor binding in major depressive disorder
  370. Premorbid personality factors in schizophrenia and bipolar disorder: Results from a large cohort study of male conscripts.
  371. The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis
  372. Antidepressant use and mortality in Finland: a register-linkage study from a nationwide cohort
  373. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial
  374. Effects of MAOA‐Genotype, Alcohol Consumption, and Aging on Violent Behavior
  375. 5-HT1A Receptors in the Frontal Cortical Brain Areas in Cloninger Type 1 and 2 Alcoholics Measured by Whole-Hemisphere Autoradiography
  376. Pharmacotherapy of Methamphetamine Addiction: An Update
  377. Brain anatomy of persistent violent offenders: More rather than less
  378. Midbrain serotonin and striatum dopamine transporter binding in double depression: A one-year follow-up study
  379. Association of serotonin transporter promoter regulatory region polymorphism and cerebral activity to visual presentation of food
  380. Predicting Forensic Admission among the Mentally Ill: A Bayesian Approach
  381. Temporal cortex dopamine D2/3 receptor binding in major depression
  382. Striatal dopaminergic terminals in type 1 and type 2 alcoholics measured with [3H]dihydrotetrabenazine and human whole hemisphere autoradiography
  383. Autoradiographic characterization of α2C‐adrenoceptors in the human striatum
  384. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia
  385. Characterization of metabolic syndrome among forensic psychiatric inpatients
  386. Antidepressant use and mortality in Finland: A register-linkage study from a nationwide cohort
  387. Cortical dopamine D1 receptors in type 1 and type 2 alcoholics measured with human whole hemisphere autoradiography
  388. Changes in midbrain serotonin transporter availability in atypically depressed subjects after oneyear of psychotherapy
  389. Correlation between the SERT binding densities in hypothalamus and amygdala in cloninger type 1 and 2 alcoholics
  390. Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents
  391. Body size and violent offending among males in the Northern Finland 1966 birth cohort
  392. Amygdala serotonin transporters in alcoholics measured by whole hemisphere autoradiography
  393. A Comparison of General Adult and Forensic Patients with Schizophrenia Living in the Community
  394. Energy substrate metabolism among habitually violent alcoholic offenders having antisocial personality disorder
  395. Real-world effectiveness of pharmacological treatments in schizophrenia
  396. Violent persons with schizophrenia and comorbid disorders: A functional magnetic resonance imaging study
  397. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [123I] nor-β-CIT SPECT imaging
  398. A Multisite Study of Community Treatment Programs for Mentally Ill Offenders With Major Mental Disorders
  399. Functional COMT Val158Met Polymorphism, Risk of Acute Coronary Events and Serum Homocysteine: The Kuopio Ischaemic Heart Disease Risk Factor Study
  400. Transmission of violent offending and crime across three generations
  401. A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence
  402. A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence
  403. Antidepressants and the Risk of Suicide, Attempted Suicide, and Overall Mortality in a Nationwide Cohort
  404. Visualization of the cortical dopamine transporter in type 1 and 2 alcoholics with human whole hemisphere autoradiography
  405. Nucleus accumbens serotonin transporters in alcoholics measured by whole-hemisphere autoradiography
  406. PMH23 PREDICTING VIOLENT OFFENDING AMONG MENTALLY ILL IN A MULTINATIONAL SETTING–NAIVE BAYESIAN FUSION AND MODEL MERGING WITH P-COURSE
  407. Midbrain binding of [123I]nor-β-CIT in atypical depression
  408. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study
  409. Midbrain dopamine D2/3 receptor binding in schizophrenia
  410. Glutamatergic drugs for schizophrenia
  411. Fatal Agranulocytosis 4 Years After Discontinuation of Clozapine
  412. P.2.c.016 Antidepressant use and the risk of suicide, attempted suicide and overall mortality in a nation-wide cohort
  413. Lower serotonin transporter binding in caudate in alcoholics
  414. Seasonal variations in [3H]citalopram platelet binding between healthy controls and violent offenders in Finland
  415. The consequences of Conduct Disorder for males who develop schizophrenia: Associations with criminality, aggressive behavior, substance use, and psychiatric services
  416. Premorbid Intellectual Functioning in Bipolar Disorder and Schizophrenia: Results From a Cohort Study of Male Conscripts
  417. Topiramate Add-On in Treatment-Resistant Schizophrenia
  418. Subcritical water as eluent for chromatographic separation of carbohydrates using cation-exchange resins
  419. Visualisation of the cortical dopamine D3 receptors in alcoholics and controls with human whole-hemisphere autoradiography
  420. Effects of Venlafaxine Treatment on Clozapine Plasma Levels in Schizophrenic Patients
  421. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
  422. Striatal dopamine D1 receptors in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  423. An Outcome of Psychodynamic Psychotherapy: A Case Study of the Change in Serotonin Transporter Binding and the Activation of the Dream Screen
  424. Dopamine and alcoholism: neurobiological basis of ethanol abuse
  425. Reduced brain serotonin transporter binding in patients with panic disorder
  426. A controlled study of tryptophan and cortisol in violent offenders
  427. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder
  428. Cortical dopamine D2receptors in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  429. Elevated midbrain serotonin transporter availability in mixed mania: a case report
  430. Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using []SB-269970
  431. THE MEDIAL TEMPORAL LOBE IN ALCOHOLISM AND PSYCHOPATHOLOGY: EVALUATION BY VOLUMETRIC MRI.
  432. MRI volumetry of the vermis and the cerebellar hemispheres in men with schizophrenia
  433. 123I-?-CIT binding and recovery from depression
  434. Brain serotonin 1A receptor binding in bulimia nervosa
  435. Characteristics and circumstances of homicidal acts committed by offenders with schizophrenia
  436. Comorbid Personality Disorders and Substance Use Disorders of Mentally Ill Homicide Offenders: A Structured Clinical Study on Dual and Triple Diagnoses
  437. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
  438. The amygdala and schizophrenia: a volumetric magnetic resonance imaging study in first-episode, neuroleptic-naive patients
  439. Treatment improves serotonin transporter binding and reduces binge eating
  440. P.3.011 Reduced brain serotonin transporter binding in patients with panic disorder
  441. Dopamine D2 receptors and transporters in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  442. Total plasma l‐tryptophan, free l‐tryptophan and competing amino acid levels in a homicidal male adolescent with conduct disorder
  443. Dopamine receptors and transporters in the brain reward circuits of type 1 and 2 alcoholics measured with human whole hemisphere autoradiography☆
  444. Ethanol consumption and DRD2 gene TaqI a polymorphism among socially drinking males
  445. Different effect of age on dopamine transporters in the dorsal and ventral striatum of controls and alcoholics
  446. Alcoholics show altered histaminergic neurotransmission in several cortical areas - Preliminary report
  447. Extrastriatal dopamine D2/3 receptor density and distribution in drug-naive schizophrenic patients
  448. Co-eluent effect in partition chromatography. Rhamnose–xylose separation with strong and weak cation-exchangers in aqueous ethanol
  449. Seasonal variation in specific methods of suicide: a national register study of 20 234 Finnish people
  450. Glutamatergic drugs for schizophrenia
  451. Is occupation relevant in suicide?
  452. Prefrontal volumes in habitually violent subjects with antisocial personality disorder and type 2 alcoholism
  453. Use of Statistical Techniques in Studies of Suicide Seasonality, 1970 to 1997
  454. A volumetric MRI study of the entorhinal cortex in first episode neuroleptic-naive schizophrenia
  455. The quantitative risk of violent crime and criminal offending: a case‐control study among the offspring of recidivistic Finnish homicide offenders
  456. Effect of alcohol abuse on human brain histamine and tele-methylhistamine
  457. Serotonin Transporter Distribution and Density in the Cerebral Cortex of Alcoholic and Nonalcoholic Comparison Subjects: A Whole-Hemisphere Autoradiography Study
  458. Analysis of monoamine oxidase A (MAOA) promoter polymorphism in Finnish male alcoholics
  459. Total serum cholesterol level, violent criminal offences, suicidal behavior, mortality and the appearance of conduct disorder in Finnish male criminal offenders with antisocial personality disorder
  460. Seclusion treatment measures and serum cholesterol levels among Finnish male forensic psychiatric patients
  461. Serum lipid levels and violence among Finnish male forensic psychiatric patients
  462. Impaired Temporal Lobe Processing of Preattentive Auditory Discrimination in Schizophrenia
  463. Dopamine Transporter Density and Novelty Seeking Among Alcoholics
  464. Mortality of antisocial male criminals
  465. Free L -tryptophan plasma levels in antisocial violent offenders
  466. Recidivism Among Serious Violent Crime Offenders in Finland
  467. SPECT and neuropsychological performance in severe depression treated with ECT
  468. Measurement of the Striatal Dopamine Transporter Density and Heterogeneity in Type 1 Alcoholics Using Human Whole Hemisphere Autoradiography
  469. Altered frontal lobe function suggested by source analysis of event-related potentials in impulsive violent alcoholics
  470. Dopamine Transporter in vitro Binding and in vivo Imaging in the Brain
  471. Dopamine Transporter in vitro Binding and in vivo Imaging in the Brain
  472. Reduced serotonin transporter binding in binge eating women
  473. Effects of ageing on serotonin transporters in healthy females
  474. A morphometric MRI study of the hippocampus in first-episode, neuroleptic-naı̈ve schizophrenia
  475. The A1 allele of the D2 dopamine receptor gene is associated with high dopamine transporter density in detoxified alcoholics
  476. Dopamine D2/D3-receptor and transporter densities in nucleus accumbens and amygdala of type 1 and 2 alcoholics
  477. Cluster C personality disorder has no independent effect on striatal dopamine transporter densities in major depression
  478. Mortality of antisocial male criminals
  479. Psychopathy and the posterior hippocampus
  480. Characterization of γ-aminobutyrate type A receptors with atypical coupling between agonist and convulsant binding sites in discrete brain regions
  481. In vivo voltammetry with removable carbon fibre electrodes in freely-moving mice: dopamine release during intracranial self-stimulation
  482. Recidivistic Violent Behavior and Axis I and Axis II Disorders
  483. Patterns of dopamine overflow in mouse nucleus accumbens during intracranial self-stimulation
  484. S19.03 Spet studies on outcome of treatment by psychosocial interventions in depression and hysterical paresthesia
  485. Specific binding and laterality of human extrastriatal dopamine D2/D3 receptors in late onset type 1 alcoholic patients
  486. Forensic Psychiatric Organization in Finland
  487. Suicidal behavior in patients with schizophrenia is related to COMT polymorphism
  488. Ethanol modulates evoked dopamine release in mouse nucleus accumbens: dependence on social stress and dose
  489. Regional cerebral blood flow during exposure to food in obese binge eating women
  490. CYP2A6 genotype and smoking
  491. A volumetric MRI study of the hippocampus in type 1 and 2 alcoholism
  492. Metabolism of [ 123 I]epidepride may affect brain dopamine D 2 receptor imaging with single-photon emission tomography
  493. Association Between the Functional Polymorphism of Catechol‐O‐Methyltransferase Gene and Alcohol Consumption Among Social Drinkers
  494. Association Between the Functional Polymorphism of Catechol-O-Methyltransferase Gene and Alcohol Consumption Among Social Drinkers
  495. Pharmacological Intervention for Preventing Violence Among the Mentally Ill with Secondary Alcohol-And Drug-Use Disorders
  496. Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior
  497. Reversed Hemispheric Asymmetry of Auditory N100m in Schizophrenics
  498. Dopamine-transporter density in nucleus accumbens of type-1 alcoholics
  499. Quantitative MRI of the hippocampus and amygdala in severe depression
  500. Dopamine transporter and D 2 -receptor density in late-onset alcoholism
  501. Erratum to “Mortality among habitually violent offenders”
  502. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects
  503. Transient Syncope and ECG Changes Associated With the Concurrent Administration of Clozapine and Diazepam
  504. Outcome of different types of long-term antidepressant treatments: a 3-year follow-up study of 14 182 patients
  505. Pindolol and Major Affective Disorders
  506. Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior
  507. Striatal dopamine transporter density in major depression
  508. Dopamine transporter availability and depressive symptoms during alcohol withdrawal
  509. Maternal Smoking During Pregnancy and Risk of Criminal Behavior Among Adult Male Offspring in the Northern Finland 1966 Birth Cohort
  510. Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism
  511. Serum testosterone levels, mental disorders and criminal behaviour
  512. Reply
  513. Mortality among habitually violent offenders
  514. Is a Large Body Size During Childhood a Risk Factor for Later Aggression?
  515. Comparison of Iodine-123 Labelled Nor-β-CIT and β-CIT as Potential Radioligands for Serotonin Transporter Imaging
  516. Schizophrenia and seasonality of admissions: the Northern Finland 1966 birth cohort study
  517. Altered Parallel Auditory Processing in Schizophrenia Patients
  518. Increasing homicide rate in Finland accompanied by decreasing seasonality over the period 1957–95
  519. Chronic pindolol treatment and major affective disorders
  520. Abnormal structure of human striatal dopamine re-uptake sites in habitually violent alcoholic offenders: a fractal analysis
  521. 83 Altered frontal lobe function suggested by erp generator analysis in impulsive violent alcoholics
  522. Fentanyl decreases ?-CIT binding to the dopamine transporter
  523. Imaging the structure of the striatum: a fractal approach to SPECT image interpretation
  524. Seasonal variation in suicide occurrence in Finland
  525. Secular trends in the rates and seasonality of violent and nonviolent suicide occurrences in Finland during 1980–95
  526. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging
  527. Resersal of cerebral asymmetry in schizophrenia measured with magnetoencephalography
  528. The metabolism of iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine (NNC 13-8241) measured in human plasma is only minor
  529. Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography
  530. The incidence and onset-age of hospitalized bipolar affective disorder in Finland
  531. Schizophrenia, alcohol abuse and violent behaviour
  532. Change in monoamine transporter density related to clinical recovery: A case-control study
  533. Fractal analysis – a new approach in brain receptor imaging
  534. Juvenile mortality, mental disturbances and criminality: a prospective study of the Northern Finland 1966 birth cohort
  535. Parental age gap and child sex ratio—Fact or fiction?
  536. Schizophrenia, Alcohol Abuse, and Violent Behavior: A 26-Year Followup Study of an Unselected Birth Cohort
  537. Iodine-123 labeled nor-?-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography
  538. Seasonal Variation in the Occurrence of Homicide in Finland
  539. Single-photon emission tomography imaging of monoamine transporters in impulsive violent behaviour
  540. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis
  541. Fractal analysis of striatal dopamine re-uptake sites
  542. Fractal analysis of striatal dopamine re-uptake sites
  543. Seasonal variation of homicide occurrence in Finland
  544. Specific major mental disorders and criminality: a 26-year prospective study of the 1966 northern Finland birth cohort
  545. Striatal and extrastriatal imaging of dopamine D 2 receptors in the living human brain with [ 123 I]epidepride single-photon emission tomography
  546. Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography
  547. Dopamine reuptake site densities in patients with social phobia
  548. Schizophrenia, alcohol abuse and violent behaviour
  549. Psychiatric disorders and violent behavior
  550. The predictors of schizophrenia in the 1966 Northern Finland birth cobort study
  551. Impaired adaptation to external input in impulsive violent alcoholics
  552. Characterization of C-11 or I-123 Labelled β-CIT‐FP and β-CIT‐FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC
  553. Characterization of C-11 or I-123 Labelled ?-CIT-FP and ?-CIT-FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC
  554. Forensic psychotherapy
  555. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography
  556. Initial human studies with single-photon emission tomography using iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine (NNC 13-8241)
  557. Mental Disorders and Homicidal Behavior in Finland
  558. Risk of homicidal behavior among discharged forensic psychiatric patients
  559. Factors associated with homicide recidivism in a 13-year sample of homicide offenders in Finland
  560. Low incidence of mania in northern Finland
  561. Schizophrenia and Homicidal Behavior
  562. Citalopram in the Treatment of Alcoholism: a Double-blind Placebo-controlled Study
  563. Quantitative Risk Assessment of Homicidal Behaviour
  564. Homicidal behaviour and mental disorders
  565. The metabolite pattern of [123I]β-CIT determined with a gradient HPLC method
  566. Drs. Tiihonen and Kuikka Reply
  567. Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics
  568. Iodine-123 labelledN-(2-fluoroethyl)-2?-carbomethoxy-3?-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain
  569. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia
  570. Imaging of serotonin and dopamine transporters in the living human brain
  571. Lipophilic metabolite of [123I]β‐CIT in human plasma may obstruct quantitation of the dopamine transporter
  572. Risk of homicidal behaviour among persons convicted of homicide
  573. Altered cerebral blood flow during hysterical paresthesia
  574. Carbamazepine-induced Changes in Plasma Levels of Neuroleptics
  575. Increase in cerebral blood flow of right prefrontal cortex in man during orgasm
  576. Eltoprazine for aggression in schizophrenia and mental retardation
  577. Long-Term Effects of Bilateral Frontal Lobe Lesions from Neuropsychiatric and Neuroradiological Aspects
  578. Magnetoencephalographic localization of epileptic cortex—impact on surgical treatment
  579. Fast decrement with stimulus repetition in ERPs generated by neuronal systems involving somatosensory SI and SII cortices: Electric and magnetic evoked response recordings in humans
  580. Neuromagnetic mismatch fields to single and paired tones
  581. Eosinophilia associated with clozapine
  582. Magnetoencephalographic 10-Hz rhythm from the human auditory cortex
  583. Reply
  584. Localization of epileptic foci using a large‐area magnetometer and functional brain anatomy
  585. Separate finger representations at the human second somatosensory cortex
  586. Early deflections of cerebral magnetic responses to median nerve stimulation
  587. Evoked responses of human auditory cortex may be enhanced by preceding stimuli
  588. Multichannel detection of magnetic compound action fields of median and ulnar nerves
  589. Paired Tone Presentation Enhances Responses of Human Auditory Cortex to Rare Frequency Changes
  590. Magnetic mu rhythm in man
  591. Evoked and Spontaneous Magnetic Activity of the Human Somatosensory Cortex
  592. Molecular characterization of a Y;15 translocation segregating in a family